About GlycoMar
Business Model
GlycoMar has a hybrid business model that exploits revenue generating products and contract research services, to reduce the investment required to meet its R & D objectives. Revenue is generated through GlycoMar’s growing contract screening service and will be generated though the marketing and/or licensing of nutritional and cosmeceutical products.
In the longer term significant value will be generated for investors through the licensing of an anti-inflammatory drug that has completed phase II clinical trails. At this point GlycoMar will seek a trade sale to a major pharmaceutical company.
The Company's core business is the discovery of new compounds from marine organisms, with a specific focus on glycobiology. We combine the capabilities for isolation and early characterisation of new compounds with primary cell based screening for identifying lead compounds. We are exploiting these capabilities to the maximum; generating short-term income through service provision and product sales, short-medium term income through early licensing deals and nutraceutical & cosmeceutical development, and long term value through drug development.